Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Repligen Corp (NASDAQ:RGEN)

27.36
Delayed Data
As of Jun 30
 +0.73 / +2.74%
Today’s Change
20.07
Today|||52-Week Range
42.22
-3.29%
Year-to-Date
Repligen (RGEN) in Focus: Stock Adds 6.9% in Session
Jun 30 / Zacks.com - Paid Partner Content
Brexit Bargains Beckon the Brave
Jun 26 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close26.63
Today’s open26.70
Day’s range25.96 - 27.36
Volume532,497
Average volume (3 months)323,315
Market cap$838.3M
Dividend yield--
Data as of 06/30/2016

Growth & Valuation

Earnings growth (last year)+12.00%
Earnings growth (this year)+67.86%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+31.45%
P/E ratio114.3
Price/Sales11.37
Price/Book6.69

Competitors

 Today’s
change
Today’s
% change
FWPForward Pharma A/S-0.19-1.03%
SRPTSarepta Therapeutics...+0.41+2.20%
INSYINSYS Therapeutics I...+0.42+3.35%
LCILannett Company Inc+0.13+0.55%
Data as of 06/30/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)$0.13
Annual revenue (last year)$83.5M
Annual profit (last year)$9.3M
Net profit margin11.19%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Tony J. Hunt
Vice President-
Global Operations
Steve Curran
Corporate headquarters
Waltham, Massachusetts

Forecasts

Partner Offers

Search for Jobs